A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity.
We studied the pharmacokinetics and toxicity of 220 mg/m2 melphalan (HDM 220) followed by autologous stem cell transplantation in 16 patients with advanced haematological malignancies. Pharmacokinetic parameters (mean values of steady-state volume of distribution 14.6 l/m2, total body clearance 313 ml/min/m2, elimination half-life 46 min) were the same as those of 140 or 200 mg/m2 melphalan in previous reports. HDM 220 was feasible. Extramedullary toxicity was mainly W.H.O. grade 4 mucositis (13/16 patients). The median duration of 41 d (10, not reached) of thrombocytopenia < 25 x 10(9)/l was long. In multiple myeloma the response rate was 89% in heavily pretreated patients, suggesting that HDM 220 could be considered earlier in the course of the disease as an alternative consolidation therapy.
Moreau
P
P
Department of Haematology, Nantes, France.
Kergueris
M F
MF
Milpied
N
N
Le Tortorec
S
S
Mahé
B
B
Bulabois
C E
CE
Rapp
M J
MJ
Larousse
C
C
Bataille
R
R
Harousseau
J L
JL
D000293:Adolescent; D000328:Adult; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006689:Hodgkin Disease / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D008297:Male; D008558:Melphalan / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D010865:Pilot Projects; D014182:Transplantation, Autologous
D008558:Melphalan